70 per cent of the top 25 Australian medtech and pharma companies are based in Victoria and nearly 60 per cent of Australia’s pharmaceutical exports are from Victoria. Victoria is home to CSL, the second largest influenza vaccine manufacturer in the world, as well as Pfizer, Sanofi, Novartis, Merck, Bristol Myers Squibb, Aspen and GSK. Victoria is the leading State in Australia for mRNA research and is adding mRNA manufacturing to its world-class biotech precinct. Victoria has long been the centre of Australia’s biotech and medical research ecosystem with the deepest research, therapeutic and clinical capability in the Asia-Pacific region. The collaboration between MIPS, the Doherty Institute and mRNA Victoria reinforces the strong mRNA research sector in Victoria as well as Australia’s leading mRNA manufacturing capability. This will be Australia’s first local mRNA COVID-19 vaccine candidate to reach Phase 1 clinical trials, with preliminary results expected to be available in the first half of 2022. MRNA Victoria is providing funding support for the Monash Institute of Pharmaceutical Sciences (MIPS) and the Doherty Institute to manufacture mRNA COVID-19 vaccines for clinical trials, due to start late 2021. Development of Australia's first mRNA vaccine The Industry Panel will comprise Victorian-based companies with relevant experience in mRNA or RNA-related manufacture, supply chain and systems support. MRNA Victoria has been working with the national industry association, AusBiotech and the BioMelbourne Network to establish a panel of industry experts and service providers to complement the expertise of the SAG.

Dr Minna-Liisa Änkö - Head, Functional RNAomics laboratory, Hudson Institute of Medical Research.

Professor Ricky Johnstone - Head, Gene Regulation Laboratory, Peter MacCallum Cancer Centre.

Professor Andrew Steer - Director, Infection and Immunity, Murdoch Children’s Research Institute.

Professor John Carroll - Director, Monash Biomedicine Discovery Institute.

Professor Terry Nolan - Head, Vaccine and Immunisation Research Group, Doherty Institute at University of Melbourne, and MCRI.Professor Doug Hilton - Director, Walter and Eliza Hall Institute of Medical Research.Professor Brendan Crabb - Director, Burnet Institute.

Professor William Charman - Sir John Monash Distinguished Professor, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University.Dr Barney Graham - Deputy Director, Vaccine Research Center, US National Institutes of Health.Professor Sharon Lewin - Director, Doherty Institute.Dr Amanda Caples - Victoria’s Lead Scientist and Chair of the Group.The Scientific Advisory Group works in consultation with mRNA Victoria, supporting the development of the mRNA ecosystem and research in Victoria. MRNA Victoria is advised by a Scientific Advisory Group made up of world-leading experts from the medical research sector. MRNA Victoria’s Scientific Advisory Group International Engagement and Investment Opportunities.Development of Australia’s first mRNA Vaccine.mRNA Victoria’s Industry Advisory Panel.mRNA Victoria’s Scientific Advisory Group.

Through grants, international market entry support, facilitating and entering into research agreements and partnerships, mRNA Victoria delivers programs to support the development and commercialisation of mRNA research. Its role is to identify key capabilities, gaps, opportunities and lead the Victorian Government’s engagement, investment and partnerships with domestic and international companies, researchers and stakeholders to build RNA capability. MRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development for pre and clinical research, commercialisation and manufacturing investments.

Spotify jobs chicago